recently opened an MCC manufacturing facility in the United States, and was actively seeking to expand its sales. In April 1995, FMC proposed to Mendell that the two firms enter into a market division agreement. Mendell did not accept FMC's invitation.<sup>1</sup>

FMC and Asahi Chemical have signed consent agreements containing the proposed consent orders. The proposed consent orders would prohibit FMC and Asahi Chemical from:

(i) Agreeing with competitors to divide or allocate markets, customers, contracts, or geographic territories in connection with the sale of MCC, or (ii) agreeing with competitors to refrain in whole or in part from producing, selling, or marketing MCC. The respondents would also be barred from inviting or soliciting such agreements not to compete.

Further, in order to eradicate the anticompetitive effects of the alleged conspiracy, FMC is barred from serving as the U.S. distributor for any competing manufacturer of MCC (including Asahi Chemical) for a period of ten years. Further, for a period of five years, FMC may not distribute in the United States any other excipient manufactured by Asahi Chemical.<sup>2</sup>

The proposed consent orders contain several limited exemptions to the abovedescribed provisions intended to permit FMC and Asahi Chemical to engage in certain lawful and pro-competitive conduct. For example, notwithstanding the broad prohibition on agreeing to divide markets, each respondent would be permitted to enter into exclusive trademark license agreements, to enforce its intellectual property rights, and to abide by reasonable restraints ancillary to lawful joint venture agreements. In any action by the Commission alleging violations of the consent order, each respondent would bear the burden of proof in demonstrating that its conduct satisfied the conditions of the exemption.

The proposed consent orders contain provisions to assist the Commission in monitoring the respondents' compliance with the orders. FMC would be required to retain copies of written communications with competing MCC manufacturers, and upon request, to make such documents available to the Commission. Asahi Chemical would be required to produce to the Commission all documents reasonably necessary for the purpose of determining or securing compliance with the consent order, without regard to whether the documents are located in the United States or in another jurisdiction.

The purpose of this analysis is to facilitate public comment on the proposed orders, and it is not intended to constitute an official interpretation of the agreements and proposed orders or to modify in any way their terms.

By direction of the Commission.

## Donald S. Clark,

Secretary.

[FR Doc. 00–33258 Filed 12–28–00; 8:45 am] BILLING CODE 6750–01–M

## OFFICE OF GOVERNMENT ETHICS

## Study Under the Presidential Transition Act of 2000 on Improving the Financial Disclosure Process for Executive Branch Presidential Nominees; Opportunity for Comment

**AGENCY:** Office of Government Ethics (OGE).

ACTION: Notice.

**SUMMARY:** The Office of Government Ethics is conducting a study under the Presidential Transition Act of 2000 on improving the financial disclosure process for executive branch Presidential nominees. This notice indicates the pendency of OGE's study and provides the public and agencies an opportunity to comment.

**DATES:** Any comments should be received by January 29, 2001.

ADDRESSES: Send any comments to the Office of Government Ethics, Suite 500, 1201 New York Avenue, NW., Washington, DC 20005–3917, Attention: Ms. Jane S. Ley. Comments may also be sent electronically to OGE's Internet Email address at usoge@oge.gov. For Email messages, the subject line should include the following reference— "Comments Regarding Financial Disclosure Process Study."

**FOR FURTHER INFORMATION CONTACT:** Jane S. Ley, Deputy Director for Government Relations and Special Projects, Office of Government Ethics, telephone: 202–208–8022; TDD: 202–208–8025; FAX: 202–208–8037.

**SUPPLEMENTARY INFORMATION:** The Office of Government Ethics is in the midst of a six-month study under section 3 of the Presidential Transition Act of 2000, Public Law 106–293 (October 12, 2000), on improving the financial disclosure process for executive branch Presidential nominees required to file reports under section 101(b) of the Ethics in Government Act of 1978 (5

U.S.C. appendix). Within six months of the date of enactment of the new law (that is, by April 12, 2001), OGE has to submit a report based on the study to the Committee on Governmental Affairs of the U.S. Senate and Committee on Government Reform of the U.S. House of Representatives.

Under the law, OGE's report will include recommendations and legislative proposals on streamlining, standardizing and coordinating the financial disclosure process and requirements for executive branch Presidential nominees as well as avoiding duplication and burden with respect to financial information disclosed to the White House, OGE, and the Senate. The report may also address other matters relevant to the process, as OGE deems appropriate. The law further provides that the recommendations and proposals cannot, if implemented, have the effect of lessening substantive compliance with any conflict of interest requirement. Presidential nominees subject to Senate confirmation are currently required to file detailed Public Financial Disclosure Reports (the Standard Form (SF) 278 for executive branch nominees) with their agencies and OGE, as well as certain financial and other information filed with the White House, on the national security position questionnaire (SF 86) processed by the Federal Bureau of Investigation, and on various questionnaires developed by the respective confirming Senate committees.

As part of its consideration of these important matters, OGE believes it would be both appropriate and helpful to give the public and agencies an opportunity to express their views. Interested persons may submit comments to OGE, to be received by January 29, 2001, regarding any specific part of the financial disclosure process study or just to give general views on the study in order to assist OGE.

Approved: December 21, 2000.

## Amy L. Comstock,

Director, Office of Government Ethics. [FR Doc. 00–33220 Filed 12–28–00; 8:45 am] BILLING CODE 6345–01–U

 $<sup>^1</sup>$  FMC's efforts to recruit Ming Tai, Wei Ming, and Mendell to enter into anticompetitive arrangements, as alleged in the complaint, support the attempted monopolization claim. See Complaint  $\P$  22. FMC's invitation to Mendell was the most patently anticompetitive of the three, and is the basis for an independent cause of action. See Complaint  $\P$  23.

<sup>&</sup>lt;sup>2</sup> An excipient is an inactive ingredient used in the manufacture of pharmaceutical products.